Butamirate

Oral
Non-productive cough

Children <18 years. 1st trimester of pregnancy.

Renal and hepatic impairment. Pregnancy (2nd to 3rd trimester) and lactation.

Significant: Somnolence, dizziness.
Gastrointestinal disorders: Diarrhoea, nausea.
Skin and subcutaneous tissue disorders: Urticaria, rash.

This drug may cause dizziness and somnolence, if affected, do not drive or operate machinery.

Symptoms: Drowsiness, dizziness, nausea, vomiting, diarrhoea, hypotension. Management: Symptomatic treatment. Administer activated charcoal or saline laxative, or perform gastric lavage. Monitor vital functions.

Concomitant use of expectorants may lead to retention of mucous in the respiratory system, which can increase the risk of bronchospasm and airway infection.

Description: Butamirate is a non-narcotic antitussive which presents nonspecific anticholinergic and antispasmodic effect, facilitating respiration. It acts centrally by diminishing the tussigenic reflex, and peripherally via a bronchospasmolytic activity enhanced by an anti-inflammatory action.
Pharmacokinetics:
Absorption: Rapidly and completely absorbed from the gastrointestinal tract. Time to peak plasma concentration: Approx 1.5 hours.
Distribution: Plasma protein binding: Approx 95%
Metabolism: Undergoes hydrolysis to phenyl-2-butyric acid and diethylaminoethoxyethanol.
Excretion: Primarily via kidneys as metabolites. Plasma elimination half-life: Approx 13 hours.

Store below 30°C. Protect from light.

Cough & Cold Preparations

R05DB13 - butamirate ; Belongs to the class of other cough suppressants.

Buckingham R (ed). Butamirate Citrate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 07/08/2018.

Butamirate 7.5 mg/5 mL Syrup (Actavis Group PTC ehf). MHRA. https://products.mhra.gov.uk/. Accessed 07/08/2018.

Sinecod Forte (Novartis Healthcare). MIMS Philippines. https://www.mims.com/philippines. Accessed 12/11/2015.